Genetics company 23andMe is in the process of raising about $200 million, as first reported by TechCrunch. The funding will reportedly be led by Sequoia and come with a $1.7 billion valuation. 23andMe offers genetic services that provide users with information about their ancestry and personal health.
News of the round comes about five months after 23andMe scored a big win for one of its products, with the US Food and Drug Administration approving a saliva-based test that assesses a person’s genetic risk for Alzheimer’s, Parkinson’s and eight other diseases. Since it was founded in 2006, the Bay Area biotech has raised hundreds of millions—but co-founder and CEO Anne Wojcicki is said to be in no rush to IPO. Here’s a look at the company’s equity funding history:
May 2007: $9M funding | $45M valuation
Q2 Hedge Funds Resource Page Now LIVE!!! Lives, Conferences, Slides And More [UPDATED 7/7 17:16 EST]
Simply click the menu below to perform sorting functions. This page was just created on 7/1/2020 we will be updating it on a very frequent basis over the next three months (usually at LEAST daily), please come back or bookmark the page. As always we REALLY really appreciate legal letters and tips on hedge funds Read More
Dec. 2009: $27.8M | $138.9M
Jan. 2011: $31M | $179M
Dec. 2012: $58M | $288.7M
Oct. 2015: $115M | $1.1B
Want more info on 23andMe? Check out its free profile.
Article by PitchBook